Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Breast (Edinburgh, Scotland)|October 4, 2015
Breast conservative surgery and local recurrenceMahdi Rezai, Stefan Kraemer, Rainer Kimmig, et al.Journal of Vascular Research|October 27, 2007
Neointimal expression of rapamycin receptor FK506-binding protein FKBP12: postinjury animal and human in-stent restenosis tissue characteristicsGerhard Bauriedel, Alexander Jabs, Stefan Kraemer, et al.Journal of Computer Assisted Tomography|November 27, 2009
Three-Tesla magnetic resonance imaging of the wrist: diagnostic performance compared to 1.5-TChristoph Stehling, Martin Langer, Rainald Bachmann, et al.Ultrasound in Medicine & Biology|April 9, 2002
High-flow priapism: a combined interventional approach with angiography and colour DopplerBjoern G Volkmer, Thomas Nesslauer, Rainer Kuefer, et al.International Journal of Breast Cancer|January 15, 2015
Intraoperative Boost Radiotherapy during Targeted Oncoplastic Breast Surgery: Overview and Single Center ExperiencesWolfram Malter, Verena Kirn, Lisa Richters, et al.Breast Care (Basel, Switzerland)|April 10, 2014
Filariasis of the axilla in a patient returning from travel abroad: a case reportMaria Roethlisberger, Rachel Wuerstlein, Michael Majores, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology AssessmentOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2017
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ETNadia Harbeck, Oleg Gluz, Matthias Christgen, et al.Pageof 1